-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $37

Benzinga·09/03/2026 13:14:22
语音播报
Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $83 to $37.